ArticleIn silico pharmacology2025
Peripheral blood, lung and brain gene signatures in recovered and deceased patients with COVID-19.
Article in In silico pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is a multi-system disease that affects not only the respiratory system but also the neurological, hematological, and immune cells and tissues. The understanding of how the virus infiltrates and impacts a diverse set of human cells is still incomplete. This work examined bulk RNA-seq data from recovered COVID-19 patients (COVID-19 survivors with or without post-acute complications) to uncover the persisting perturbations in biological pathways. The investigation also analyzed the transcriptomic signatures in the lungs and brain tissues of deceased patients during the acute phase of infection to understand COVID-19 impact on these organs. In recovered COVID-19 patients, the severity of acute COVID-19 influenced the subsequent disturbance of gene expression patterns in the post-acute disease phase. Gene expression patterns in the lungs and brain tissues of deceased COVID-19 patients correlate with the diverse pulmonary and neurological symptoms observed in these patients. We have detected significant alterations in the expression of mitochondrial genes, such as COX7C, COX7A2, ATP5PO, ATP5F1C and NDUFB8, which reflect a compensatory upregulation in response to viral suppression of mitochondrial function. This COVID-19 induced response persists up to 24 weeks post-infection, suggesting a sustained effort of the host to mitigate mitochondrial dysfunction. Additionally, in critical and severe COVID-19 cases, gradual upregulation of UBE3A expression was detected, which previously has been linked to favorable COVID-19 outcomes. Long-term anosmia related SHH gene was upregulated in recovered critically-ill COVID-19 patients. IL6 emerged as a central hub gene consistently expressed in both lung and brain tissues of deceased COVID-19 patients, underscoring its role in driving the inflammatory pathophysiology of COVID-19 within these organs. Collectively, our study emphasizes IL6 as a central cytokine driving the inflammatory response in both lung and brain tissues, and demonstrates the virus's capacity to induce long-lasting changes in nuclear-encoded mitochondrial gene expression in the blood of recovered patients. Our findings have significant implications for developing targeted interventions for post-COVID-sequelae. Supplementary Information: The online version contains supplementary material available at 10.1007/s40203-025-00450-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.